Sang-Woo Park
Chief Executive Officer at NKMAX CO., LTD.
Net worth: 759 198 $ as of 2024-03-30
Profile
Sang-Woo Park is the founder of NKMAX Co., Ltd.
(founded in 2002) and NKGen Operating Biotech, Inc. (founded in 2002).
He is also the founder of NKGen Biotech, Inc. Mr. Park's current jobs include Chief Executive Officer & Director at NKMAX Co., Ltd.
(South Korea), Chief Executive Officer at ATGen Canada, Inc., Chief Executive Officer at ATGen America, Inc., Chief Executive Officer at Atgen H&D, Chief Executive Officer at coAsia Biotech Corp., Chief Executive Officer at Nkmax H&D Co. Ltd., Chief Executive Officer at Atgen Japan, and Chief Executive Officer at Nkmax Japan, Inc. Mr. Park's former job was Chief Executive Officer & Director at J way Co., Ltd.
He completed his undergraduate degree at Korea University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
1.82% | 2023-12-12 | 397,378 ( 1.82% ) | 751 044 $ | 2024-03-30 |
NKMAX CO., LTD.
0.01% | 2024-01-25 | 5,418 ( 0.01% ) | 8 154 $ | 2024-03-30 |
Sang-Woo Park active positions
| Companies | Position | Start |
|---|---|---|
| NKMAX CO., LTD. | Chief Executive Officer | 2002-01-13 |
| ATGen America, Inc. | Chief Executive Officer | 2014-01-31 |
| ATGen Canada, Inc. | Chief Executive Officer | 2013-08-31 |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Chief Executive Officer | 2015-12-31 |
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Chief Executive Officer | 2001-12-31 |
| Nkmax H&D Co. Ltd. | Chief Executive Officer | 2016-05-31 |
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Chief Executive Officer | 2016-03-31 |
| Atgen Japan | Chief Executive Officer | 2017-08-31 |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Founder | 2001-12-31 |
| ░░░░░ ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Former positions of Sang-Woo Park
| Companies | Position | End |
|---|---|---|
| ░ ░░░ ░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Training of Sang-Woo Park
| Korea University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| J WAY CO., LTD. | Consumer Services |
| NKMAX CO., LTD. | Health Technology |
| Private companies | 9 |
|---|---|
| ATGen Canada, Inc. | |
| ATGen America, Inc. | |
Atgen H&D
Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Health Technology |
NKMAX Co., Ltd.
NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Health Technology |
coAsia Biotech Corp.
coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Health Technology |
| Nkmax H&D Co. Ltd. | |
| Atgen Japan | |
NKGen Biotech, Inc.
NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Health Technology |
| Nkmax Japan, Inc. |
- Stock Market
- Insiders
- Sang-Woo Park
